AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31228760 — intervention group
Group type: COMPARATOR
Intervention: PDS (protocol-directed sedation)
Number of subjects: 90
Study 31228760 — intervention group
Group type: COMPARATOR
Intervention: PDS + DSI (protocol-directed sedation + daily sedation interruption)
Number of subjects: 90
Study 29197140 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN+SOF+RBV for 12 weeks (n=155, genotypes 1 and 6)
Number of subjects: 686
Study 29197140 — intervention group
Group type: COMPARATOR
Intervention: SOF+RBV for 12-24 weeks (n=531, all genotypes)
Number of subjects: 686
Study 29197140 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving SVR-12
Number of subjects: 686
Study 29197140 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-free treatment
Number of subjects: 686
Study 26192385 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT) for obesity
Number of subjects: 148
Study 24814566 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS stimulation over the right DLPFC at 2 mA for 30 min for five days
Number of subjects: 0
Study 24814566 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 21712301 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric label
Number of subjects: 322
Study 21712301 — intervention group
Group type: COMPARATOR
Intervention: No psychiatric label (Control)
Number of subjects: 322
Study 19788440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate (n=11)
Number of subjects: 22
Study 19788440 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, n=11)
Number of subjects: 22
Study 18591307 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 322
Study 18591307 — intervention group
Group type: COMPARATOR
Intervention: Control (no Burch colposuspension)
Number of subjects: 322
Study 16496603 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with autonomic neuropathy (DM-N(+))
Number of subjects: 55
Study 16496603 — intervention group
Group type: COMPARATOR
Intervention: Control patients on atropine (K-A)
Number of subjects: 55
Study 16496603 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients without autonomic neuropathy (DM-N(-))
Number of subjects: 55
Study 16496603 — intervention group
Group type: COMPARATOR
Intervention: Control patients on propranolol (K-P)
Number of subjects: 55
Study 16496603 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetics after administration of atropine (K-A)
Number of subjects: 55
Study 11932840 — intervention group
Group type: EXPERIMENTAL
Intervention: Group analysis of evaluations
Number of subjects: 100
Study 11932840 — intervention group
Group type: EXPERIMENTAL
Intervention: Group analysis of evaluations (treatment questions)
Number of subjects: 100
Study 11932840 — intervention group
Group type: EXPERIMENTAL
Intervention: Group analysis of evaluations (differential diagnosis questions)
Number of subjects: 100
Study 11932840 — intervention group
Group type: EXPERIMENTAL
Intervention: Group analysis of evaluations (prognosis questions)
Number of subjects: 100
Study 11932840 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training
Number of subjects: 100
Study 10096582 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral triple combination therapy (after 1996)
Number of subjects: 1027
Study 10096582 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral triple combination therapy (before 1996)
Number of subjects: 1027
Study 8562300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone hydrochloride 200 mg twice daily for 6 days
Number of subjects: 18
Study 8562300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg four times daily for 6 days
Number of subjects: 18
Study 8562300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone hydrochloride 200 mg twice daily + Cimetidine 300 mg four times daily for 6 days
Number of subjects: 18
Study 2147630 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 injections regimen (basal-prandial with short-acting insulin before meals and isophane (NPH) insulin at bedtime)
Number of subjects: 43
Study 2147630 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 injections regimen (4 injections plus a second injection of isophane (NPH) insulin before breakfast)
Number of subjects: 43
Study 2147630 — intervention group
Group type: COMPARATOR
Intervention: 4 injections regimen
Number of subjects: 43
Study 2147630 — intervention group
Group type: COMPARATOR
Intervention: 5 injections regimen
Number of subjects: 43
Study 2147630 — intervention group
Group type: COMPARATOR
Intervention: 4 injections regimen and 5 injections regimen
Number of subjects: 43
Study 30948335 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional p53 mutations
Number of subjects: 41
Study 30948335 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of p53, Δ40p53, and Δ133p53 isoforms in mutant (MT) p53 RCC
Number of subjects: 41
Study 30948335 — intervention group
Group type: COMPARATOR
Intervention: Expression of Δ133p53 isoform in WT p53 tissues
Number of subjects: 41
Study 30948335 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in patients with functional p53 mutation
Number of subjects: 41
Study 30948335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor stage and p53 mutation
Number of subjects: 41
Study 28289894 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (gallium‐aluminum‐arsenide diode laser, 20 mW, applied in five doses)
Number of subjects: 15
Study 28289894 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard protocol for distalization)
Number of subjects: 15
Study 28289894 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 15
Study 25879572 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education plus implementation intentions and mental imagery
Number of subjects: 0
Study 25879572 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education plus implementation intentions and mental imagery with text messages
Number of subjects: 0
Study 25879572 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education control condition
Number of subjects: 0
Study 22116961 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMA protocol treatment by TIMA-trained psychiatrists over a 12-week period
Number of subjects: 40
Study 22116961 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMA protocol treatment
Number of subjects: 40
Study 21342376 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 80 mg monthly maintenance dose
Number of subjects: 134
Study 21342376 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 160 mg monthly maintenance dose
Number of subjects: 134
Study 21342376 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg monthly
Number of subjects: 134
Study 19247490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered on the parietal cortex
Number of subjects: 0
Study 19247490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered on the premotor cortex (PM)
Number of subjects: 0
Study 17901084 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-sampling and testing
Number of subjects: 626
Study 17901084 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based testing
Number of subjects: 626
Study 15654489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanecol chloride tablets (20 mg, as needed)
Number of subjects: 12
Study 15654489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11573633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm dressing (group T)
Number of subjects: 111
Study 11573633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm dressing plus filter‐shoulder fixation (group F)
Number of subjects: 111
Study 11573633 — intervention group
Group type: EXPERIMENTAL
Intervention: Niko Epi‐Fix dressing (group N)
Number of subjects: 111
Study 9577354 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN) for 7 days
Number of subjects: 34
Study 9577354 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN) for 7 days
Number of subjects: 34
Study 7604754 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine sulphate capsule
Number of subjects: 6
Study 7604754 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine dihydrochloride plain tablet
Number of subjects: 6
Study 7604754 — intervention group
Group type: COMPARATOR
Intervention: Quinine sulphate sugar coated tablet
Number of subjects: 6
Study 7604754 — intervention group
Group type: COMPARATOR
Intervention: Quinine hydrochloride (IV infusion)
Number of subjects: 6
Study 3075630 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheniramine maleate (supplement) for the first 3 months
Number of subjects: 120
Study 3075630 — intervention group
Group type: COMPARATOR
Intervention: Clofazimine and dapsone (control) for 12 months without supplement
Number of subjects: 120
Study 30629121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB)
Number of subjects: 670
Study 30629121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise
Number of subjects: 670
Study 30629121 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise (control)
Number of subjects: 670
Study 28707741 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological counselling plus sleep adjuvant measures
Number of subjects: 74
Study 28707741 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological counselling alone
Number of subjects: 74
Study 28707741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep adjuvant measures alone
Number of subjects: 74
Study 28707741 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 74
Study 25956819 — intervention group
Group type: EXPERIMENTAL
Intervention: ThuVEP
Number of subjects: 29
Study 25956819 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 29
Study 23201969 — intervention group
Group type: EXPERIMENTAL
Intervention: Essentialist mind-set
Number of subjects: 0
Study 23201969 — intervention group
Group type: COMPARATOR
Intervention: Non-essentialist mind-set (control)
Number of subjects: 0
Study 22104550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diets
Number of subjects: 932
Study 22104550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diets
Number of subjects: 932
Study 22104550 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 932
Study 19025407 — intervention group
Group type: EXPERIMENTAL
Intervention: 830-nm diode laser treatment (10 Hz, 50% duty cycle, 60 mW, 9.7 J/cm²) for 2 weeks, 10-min sessions, 5 days a week
Number of subjects: 36
Study 19025407 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham laser treatment)
Number of subjects: 36
Study 19025407 — intervention group
Group type: EXPERIMENTAL
Intervention: 830-nm diode laser treatment
Number of subjects: 36
Study 16875929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTT binding in bipolar disorder subjects
Number of subjects: 55
Study 16875929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTT binding in bipolar disorder subjects with anxiety symptoms
Number of subjects: 55
Study 16875929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTT binding in bipolar disorder subjects with pathological obsessions and compulsions
Number of subjects: 55
Study 16875929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTT binding in bipolar disorder subjects with a history of suicide attempts
Number of subjects: 55
Study 16875929 — intervention group
Group type: COMPARATOR
Intervention: 5-HTT binding in healthy controls
Number of subjects: 55
Study 12616405 — intervention group
Group type: EXPERIMENTAL
Intervention: New special senior shoes with higher heel height
Number of subjects: 26
Study 12616405 — intervention group
Group type: EXPERIMENTAL
Intervention: New special senior shoes with lower heel height
Number of subjects: 26
Study 12616405 — intervention group
Group type: COMPARATOR
Intervention: Habitual shoes
Number of subjects: 26
Study 12616405 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation after five weeks with new shoes
Number of subjects: 26
Study 10720170 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified food
Number of subjects: 208
Study 10720170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever prevalence
Number of subjects: 208
Study 10720170 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea prevalence
Number of subjects: 208
Study 10720170 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated C-reactive protein levels
Number of subjects: 208
Study 10720170 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight at birth or at 1 month of age
Number of subjects: 208
Study 10720170 — intervention group
Group type: EXPERIMENTAL
Intervention: More rapid weight gain
Number of subjects: 208
Study 10720170 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status
Number of subjects: 208
Study 9445577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 8.03 mg
Number of subjects: 320
Study 9445577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 16.06 mg
Number of subjects: 320
Study 9445577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate 10 mg
Number of subjects: 320
Study 9445577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate 20 mg
Number of subjects: 320
Study 9445577 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg
Number of subjects: 320
Study 9445577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 9445577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 320
Study 9445577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate
Number of subjects: 320
Study 1548998 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise regimen (12 weeks, 1 hour sessions, 3 days/week: 20 min cycle exercise at 60-80% HRreserve followed by 35 min strength and flexibility training)
Number of subjects: 37
Study 1548998 — intervention group
Group type: COMPARATOR
Intervention: Counseling control condition
Number of subjects: 37
Study 1548998 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Number of subjects: 37
Study 3919975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of food (mixed breakfast)
Number of subjects: 6
Study 30169405 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20 μg/kg and atropine 10 μg/kg
Number of subjects: 85
Study 30169405 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 85
Study 28962662 — intervention group
Group type: EXPERIMENTAL
Intervention: ANTICOAGULATION CHOICE conversation tool
Number of subjects: 999
Study 28962662 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 999
Study 26275330 — intervention group
Group type: EXPERIMENTAL
Intervention: Home assessment
Number of subjects: 731
Study 26275330 — intervention group
Group type: COMPARATOR
Intervention: Clinic follow-up
Number of subjects: 731
Study 23470704 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuity-adaptable patient room
Number of subjects: 2
Study 23470704 — intervention group
Group type: COMPARATOR
Intervention: Transitional care process
Number of subjects: 2
Study 22009803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime with ampicillin
Number of subjects: 135
Study 22009803 — intervention group
Group type: COMPARATOR
Intervention: Amikacin with ampicillin
Number of subjects: 135
Study 18166839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1 and 8 plus cisplatin 80 mg/m2 on day 1 (GC)
Number of subjects: 87
Study 18166839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1 and 8 plus paclitaxel 200 mg/m2 on day 1 (GP)
Number of subjects: 87
Study 18166839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1 (GCb)
Number of subjects: 87
Study 18166839 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with gemcitabine (all regimens)
Number of subjects: 87
Study 16408151 — intervention group
Group type: EXPERIMENTAL
Intervention: Client's rating of the working alliance at 3 months and 15 months post baseline
Number of subjects: 115
Study 16408151 — intervention group
Group type: EXPERIMENTAL
Intervention: Case manager's rating of the working alliance at 3 months and 15 months post baseline
Number of subjects: 115
Study 15560162 — intervention group
Group type: EXPERIMENTAL
Intervention: Viagra (individually adjusted dose for 6 months)
Number of subjects: 218
Study 15560162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialis (20 mg for 6 months)
Number of subjects: 218
Study 15560162 — intervention group
Group type: EXPERIMENTAL
Intervention: Impase (1 tablet every other day sublingually for 6 months)
Number of subjects: 218
Study 15560162 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PDE‐5 inhibitors (Viagra, Sialis) and Impase
Number of subjects: 218
Study 11693769 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted ablation of atrial ectopic foci concentrated in the pulmonary veins
Number of subjects: 0
Study 9038595 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (12-month program, building up to 20.4 +/- 3.8 min/day)
Number of subjects: 84
Study 9038595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study 8477555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral racemic ibuprofen (400 mg)
Number of subjects: 10
Study 8477555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous racemic ibuprofen (60-minute infusion)
Number of subjects: 10
Study 2892874 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 10
Study 2892874 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 10
Study 2892874 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 30020987 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-week Yin yoga intervention
Number of subjects: 105
Study 30020987 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-week intervention combining Yin yoga with psychoeducation and mindfulness (YOMI program)
Number of subjects: 105
Study 30020987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga or mindfulness practice)
Number of subjects: 105
Study 27384536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized designs
Number of subjects: 0
Study 27384536 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency research
Number of subjects: 0
Study 27384536 — intervention group
Group type: COMPARATOR
Intervention: Other designs
Number of subjects: 0
Study 24554962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-warmed serum (37°C)
Number of subjects: 62
Study 24554962 — intervention group
Group type: COMPARATOR
Intervention: Room temperature serum (25.5°C)
Number of subjects: 62
Study 22854639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (75 µg or 3,000 IU per day)
Number of subjects: 130
Study 22854639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 20231324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus Naltrexone (200 mg/day + 100 mg/day)
Number of subjects: 170
Study 20231324 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (100 mg/day)
Number of subjects: 170
Study 20231324 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (200 mg/day)
Number of subjects: 170
Study 20231324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 19278081 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% zinc citrate fluoride dentifrice
Number of subjects: 43
Study 19278081 — intervention group
Group type: COMPARATOR
Intervention: commercial fluoride dentifrice
Number of subjects: 43
Study 19278081 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 43
Study 15767536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (100 mg) every other week by intramuscular injection
Number of subjects: 38
Study 15767536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent volume) every other week by intramuscular injection
Number of subjects: 38
Study 11729638 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (lipase inhibitor)
Number of subjects: 0
Study 11729638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomma Herb's extract (CT‐II)
Number of subjects: 0
Study 11729638 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (fat substitute)
Number of subjects: 0
Study 11729638 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitors (inhibitors of carbohydrate absorption)
Number of subjects: 0
Study 9041328 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal plasma RNA levels
Number of subjects: 326
Study 9041328 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment groups in mean plasma RNA level
Number of subjects: 326
Study 9041328 — intervention group
Group type: EXPERIMENTAL
Intervention: Average change over time
Number of subjects: 326
Study 9041328 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve
Number of subjects: 326
Study 9041328 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum plasma RNA level
Number of subjects: 326
Study 7523914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exposure to arsenic via drinking water (412 micrograms/l)
Number of subjects: 0
Study 7523914 — intervention group
Group type: COMPARATOR
Intervention: Control group (drinking water with arsenic average levels of 37.2 micrograms/l)
Number of subjects: 0
Study 3452274 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (230 mg)
Number of subjects: 20
Study 3452274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30006327 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended care self-management program (Partner in Balance)
Number of subjects: 81
Study 30006327 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (usual care)
Number of subjects: 81
Study 27213613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lancet weight of 25 g
Number of subjects: 20